5 Innovative Applications of Modular Cleanrooms in Cell and Gene Therapy

The cell and gene therapy industry is evolving at a breakneck pace, driven by breakthroughs in personalized medicine, CRISPR gene editing, and advanced therapies (ATMPs). Yet, the infrastructure supporting these innovations has often struggled to keep up—until modular cleanrooms emerged as a transformative solution. Unlike traditional “stick-built” cleanrooms, which are costly, slow to construct, and rigid, modular systems offer flexibility, speed, and efficiency. Here are five innovative ways they’re reshaping cell and gene therapy manufacturing.

1. Accelerating ATMP Production Facility Deployment

Advanced Therapy Medicinal Products (ATMPs)—including cell therapies, gene therapies, and tissue-engineered products—require ultra-clean environments to ensure safety and efficacy. Traditional cleanrooms can take 12–18 months to build, delaying critical therapies from reaching patients. Modular cleanrooms, by contrast, are pre-engineered and prefabricated off-site, slashing construction time to 3–6 months.

This rapid deployment was exemplified by Penn Medicine, which used modular cleanrooms to fast-track the launch of its cell and gene therapy program. By reducing facility lead times, manufacturers can respond faster to regulatory approvals and clinical demand, getting life-saving treatments to patients sooner.

2. Enabling Small-Scale, Personalized Therapy Production

Cell and gene therapies are often personalized—tailored to individual patients, as seen in CAR-T cell therapies that use a patient’s own immune cells. This requires small-batch production, a challenge for large, inflexible traditional cleanrooms designed for mass manufacturing.

Modular cleanrooms solve this with scalable, compact designs. Their prefabricated components can be configured into small, dedicated spaces optimized for personalized workflows, minimizing cross-contamination risks. Whether producing 10 patient-specific doses or scaling to 100, modular systems adapt without the need for extensive renovations, making personalized medicine more feasible and cost-effective.

3. Supporting Decentralized Manufacturing Networks

Historically, cell and gene therapies have been produced in large, centralized facilities, leading to logistical hurdles: delicate biological materials degrade during shipping, and delays can compromise treatment efficacy. Modular cleanrooms enable a shift toward decentralized manufacturing—smaller, regional facilities located closer to hospitals and patients.

These compact, portable units can be deployed in urban medical centers or research hubs, reducing transport times for sensitive cell samples. For example, a cancer center could house a modular cleanroom to produce CAR-T therapies on-site, eliminating the need to ship cells across the country. This not only improves therapy viability but also expands access to treatments in underserved regions.

4. Integrating Automation and Smart Monitoring

Cell and gene therapy manufacturing demands precision—even minor contamination or process variability can render a batch unusable. Modular cleanrooms are uniquely suited to integrate with automation tools (e.g., robotic cell handlers) and IoT-based monitoring systems, reducing human error and enhancing quality control.

Prefabricated designs allow for seamless integration of HEPA filtration, airflow controls, and real-time sensors that track particle counts, temperature, and humidity. Data from these systems is instantly analyzed, alerting operators to deviations before they impact production. This “smart” infrastructure ensures consistent, compliant manufacturing—critical for meeting strict regulatory standards in ATMP production.

5. Reducing Costs and Enhancing Sustainability

Traditional cleanrooms are not only slow to build but also expensive, with high labor and material costs. Modular systems cut upfront expenses by 30–50% through standardized production and reduced on-site labor. Their flexibility also lowers long-term costs: instead of building new facilities to accommodate growth, manufacturers can expand modular units by adding prefab components.

Sustainability is another key advantage. Modular cleanrooms use recycled materials in construction and generate less waste than traditional builds. Their energy-efficient designs, including variable-speed HVAC systems and LED lighting, align with the industry’s push toward greener manufacturing—an increasingly important factor for regulatory compliance and public trust.

The Future of Modular Cleanrooms in Cell and Gene Therapy

As cell and gene therapies continue to revolutionize medicine, modular cleanrooms will play a pivotal role in overcoming infrastructure barriers. Their speed, scalability, and adaptability address the unique challenges of ATMP production—from personalized medicine to decentralized networks. By combining innovation with practicality, these systems are not just buildings; they’re enablers of the next generation of life-saving treatments. For manufacturers and patients alike, modular cleanrooms are more than a trend—they’re the future of therapy production.